

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/820,155
Filing Date	April 8, 2004
First Named Inventor	Lelf KONGERSLEV
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	KONGERSLEV

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MM	AA	Aittoniemi, J., Miettinen, A., Laine, S., Sinisalo, M., Laippala, P., Vilpo, L., Vilpo, J. (1999), Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia, <u>Leuk Lymphoma</u> Jul;34(34):3815	
	AB	Christiansen, O.B., Kilpatrick, D.C., Souter, V., Varming, K., Thiel, S., Jensenius, J.C. (1999) Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. <u>Scand. J. Immunol.</u> , 49, 193-196	
	AC	van Emmerik, LC, Kuijper, EJ, Fijen, CAP, Dankert, J, and Thiel, S (1994) Binding of mannan-binding protein to various bacterial pathogens of meningitis. <u>Clin.Exp.Immunol.</u> 97:411-416.	
	AD	Fischer, PB, Ellerman-Eriksen, S, Thiel, S, Jensenius, JC, and Mogensen, SC (1994) Mannan-binding protein and conglutinin mediate enhancement of herpes simplex virus type-2 infection in mice. <u>Scand J Immunol</u> 39:439-445.	
	AE	Garred, P, Harboe, M, Oettinger, T, Koch, C, and Svejgaard, A (1994) Dual role of mannanbinding protein in infections: Another case of heterosis? <u>Eur.J.Immunogen.</u> 21:125-131.	
	AF	Garred P, Madsen HO, Hofmann B and Svejgaard A (1995) Increased frequency of homozygosity of abnormal mannan binding protein alleles in patients with suspected immunodeficiency. <u>Lancet</u> , 346: 941-943	
	AG	Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, Zurakowski D, Ezekowitz AB, Van Helden PD (1999) Mannose-binding protein B allele confers protection against tuberculous meningitis. <u>Pediatr Res</u> 45:459-64	
	AH	Holmskov, U., Malhotra, R., Sim, R.B., and Jensenius, J.C. (1994) Collectins: collagenous C-type lectins of the innate immune defense system. <u>Immunol.Today</u> 15:67-74.	
	AI	Holmskov, U., Thiel, S., Jensenius, J.C. (2003) Collectins and ficolins: Humoral lectins of the innate immune defense. <u>Annu. Rev. Immunol.</u> 21:547-578.	
✓	AJ	Jack DL, Dodds AW, Anwar N, Ison CA, Law A, Frosch M, Turner MW and Klein NJ (1998) Activation of complement by Mannose-binding lectin on isogenic mutants of <i>Neisseria meningitidis</i> serogroup B. <u>J Immunol</u> 160: 1346-1353	
	AK	Janeway CA, Travers P, Walport M and Capra JD (1999) Immunobiology, the immune system in health and disease, <u>Immunobiology</u>, Fourth Edition, Churchill Livingstone.	
MM	AL	Kilpatrick, D.C. (2002) Mannan-binding lectin: clinical significance and applications. <u>Biochim. Biophys. Acta</u> 1572:401-413. Turner, M.W. (1996) Mannose-binding lectin: the pluripotent molecule of the innate immune system. <u>Immunol.Today</u> 17:532-540.	
	AM	Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kuhl J. (1999) Assessment of measuring circulating levels of interleukin6, interleukin8, Creactive protein, soluble Fc gamma receptor type III, and mannosebinding protein in febrile children with cancer and neutropenia. <u>Clin Infect Dis</u> , Aug;29(2):4149.	
	AN	Lipscombe, R.J., Sumiya, M., Summerfield, J.A. & M.W. Turner (1995) Distinct physicochemical characteristics of human mannose-binding protein expressed by individuals of differing genotype. <u>Immunology</u> 85:660-667.	
✓	AO	Lu, J., Thiel, S., Wiedemann, H., Timpl, R. & K.B.M. Reid (1990) Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r ₂ C1s ₂ complex, of the classical pathway of complement without involvement of C1q. <u>J. Immunol.</u> 144:2287-2294.	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

[illegible]

Examiner Signature	/Mary Mosher/	Date Considered	07/09/2007
-----------------------	---------------	--------------------	------------

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.